ZURICH (Reuters) - Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an ...
In the latest iteration of See Your Risks, Bayer takes aim at denial among millennials and Gen Xers when it comes to heart ...
Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...
The optimism is rooted in new launches, Stefan Oelrich, head of Bayer’s pharma division ... we will address right where the sweet spot for us is,” Oelrich said. JPM25: After BridgeBio touts ...
It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name. The two companies said the transaction ...
Through rigorous assessment and prioritization, Bayer Pharmaceuticals is now fully ... has recently been initiated (outside of the US). The open-label, first-in-human, dose escalation study ...
The tariffs would add to the difficulties faced by the European automobile sector due to a lacklustre market at home, higher ...
The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...
Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.
Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions underway for key growth drivers darolutamide, finerenone, and elinzanetant.